BRAF and cancer: New therapies introduced since that time include ipilimumab (an immunomodulator), vemurafenib (a mutant-selective BRAF inhibitor approved for patients with a BRAFV600 mutation), and most recently dabrafenib (a different BRAF inhibitor) and trametinib (a MEK inhibitor which is also approved for BRAF-mutated cancers).